BioSante Pharma (BPAX) Tops Q3 EPS by 2c; Bio-T-Gel Gets New PDUFA Date
Tweet
Share
E-mailGet Alerts BPAX Hot Sheet
Price: $1.09 --0%
Financial Fact:
Depreciation and amortization: 5.97M
Today's EPS Names:
TAYD, PKE, More
Financial Fact:
Depreciation and amortization: 5.97M
Today's EPS Names:
TAYD, PKE, More
Join SI Premium – FREE
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reported Q3 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $182,780 versus the consensus estimate of $30,000.
Announced its Bio-T-Gel was assigned a new PDUFA date of Feb. 14th, 2012.
Announced its Bio-T-Gel was assigned a new PDUFA date of Feb. 14th, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Nike (NKE) Tops Q1 EPS by 4c
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Create E-mail Alert Related Categories
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
